Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca's proprietary Immune Repertoire Capture technology profiles a patient's immune response at the single-cell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
08/17/17	$35,000,000	Series B	Cormorant Asset Management Wellington Management Company	undisclosed
09/13/18	$125,000,000	Series C	Aisling Capital Boxer Capital Cormorant Asset Management EcoR1 Capital Redmile Group Samsara BioCapital Tavistock Group Tekla Capital Management Wellington Management Company	undisclosed